Member Info for blackrocktrader

At what value ?????

with an enormous intellectual capabilities , top scientists , agile , alert , monitoring current development and response with speed . Seems like a step ahead of the pandemic .

Boris talked about the new mutation which was found out in travellers arriving to Japan from Brazil . The government will introduce new measures . This will put P.M. in pole position in fight against covid . III World War is on .

Also a testing company .The Times : Sourcebio is looking for the contract to be extended when delayed framework is set to be awarded from next month.

Lower chart . Click on pcr tests and then cumulative . https://coronavirus.data.gov.uk/details/testing

Cumulative pcr testing since 1 May , now over 50 mln . How many by ncyt and at what price per test ??? ( the lower chart )
https://coronavirus.data.gov.uk/details/testing

Are over 300k . What percentage are done by Ncyt ?
https://coronavirus.data.gov.uk/details/testing

This is what brought the share price down after good morning open .

Importo Compresivo : total1 506 300 euro.
https://aoucagliari.it/home/it/agid_risultati_ricerca.page?search=Genesig&frame7_item=1

I remember someone posted link to the contract of one hospital in Sardynia using Ncyt technoloy worth circa 1.5 mln Euro . Asking at the end what if ncyt can supply few hundred such hospitals.

what about sells to foreign countries ???? All analyses are based on uk !!!!!!!!!!!

70% efficacy . Is that good ???????

From the half year's results : The Directors reiterate guidance announced on 13 July 2020; given the visibility of orders, extended contracts and the launch of new COVID-19 related products, revenue for the second half of the year is expected to be greater than the first half of the year and margins to be at least at a similar level. Full year revenues are expected to exceed €150 million and EBITDA profitability to exceed €100 million. The Company expects this rate of financial performance to extend into the first half of 2021. The Directors remain confident in and excited by the prospects of the business, not only for the short-term, but also for the longer-term.
And afterwards he have had DHSC contract and info about five-fold increase in pcr machine production.

£2b ????!!!!!!!!!!!!!

Yeah , just that we bit expectations .

ALTHOUGH DELAYS TO vaccines are common,
given the positive slew of positive news over
the last few weeks the three-month delay to the
possible market launch of the GlaxoSmithKline
(GSK) vaccine candidate (in partnership with
Sanofi) was unfortunate.
The two companies now plan a new study
GLAXOSMITHKLINE
(GSK) £14.00
NOVACYT
(NCYT:AIM) 870.2p
Gain to date: 6%
Original entry point:
Buy at £13.21, 5 November 2020
Gain to date: 37.7%
Original entry point:
Buy at 632p, 8 October 2020
SHARES SAYS: ?
Despite somewhat divergent fortunes of late these
are both still buys. [MG]
starting in February with an improved
formulation which will include a comparison
with an authorized Covid-19 vaccine.
If the data from the trial is as hoped, a final
trial will begin in the second quarter. Positive
results from this trial would then lead to
regulatory submissions in the second half of
2021, delaying the vaccine’s potential availability
from mid-year to the final quarter.
Importantly there are no significant financial
implications attached to the delay.
In a more positive Covid-linked corporate
development Novacyt (NCYT:AIM) added to its
diagnostic capabilities with the launch of a test
(14 Dec) for the mutation of the Covid-19 virus
associated with Danish Minks.
The mutation is of concern to scientists
because it causes an amino acid change which
affects antibody binding. The launch of the test
puts Novacyt in a strong position should the need
arise to differentiate the new strain.

Exactly

Lets hope in others countries authorities see which test is better.

Sorry . But where is novacyt mentioned in this info.

162 people got placebo out of 170 people who contracted . 162 / 170 = 0.95 so 95% efficacy .